Author: Xu, Yingying; Yuen, Pak-Wai; Lam, Jenny Ka-Wing
Title: Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives Document date: 2014_7_10
ID: 0bma2749_45
Snippet: There are also several molecules being investigated to target APCs in general. One of the most widely studied molecules is the Flt3 ligand. Flt3 ligand is a growth factor that stimulates the proliferation of hematopoietic cells. It binds to the fms-like tyrosine kinase receptor Flt3. Flt3 expression is, in hematopoietic tissue, restricted to CD34 + progenitors, including DC progenitors. In vivo treatment of Flt3 ligand is found to up-regulate the.....
Document: There are also several molecules being investigated to target APCs in general. One of the most widely studied molecules is the Flt3 ligand. Flt3 ligand is a growth factor that stimulates the proliferation of hematopoietic cells. It binds to the fms-like tyrosine kinase receptor Flt3. Flt3 expression is, in hematopoietic tissue, restricted to CD34 + progenitors, including DC progenitors. In vivo treatment of Flt3 ligand is found to up-regulate the number of DCs, but not their activation [125, 126] . Furthermore, Flt3 ligand treatment could also enhance immune response when delivered via the mucosal route [127] . It has been reported that when plasmid DNA encoding Flt3 ligand was co-administered with plasmids encoding protein antigens, effective immune responses were induced [128] . In addition to its APCs targeting ability, Flt3 ligand is an efficient and safe mucosal adjuvant that facilitated expansion of DCs following nasal administration [129, 130] .
Search related documents:
Co phrase search for related documents- immune response and mucosal adjuvant: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- immune response and mucosal route: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- immune response and plasmid dna: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32
- immune response and protein antigen: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
- immune response and target ability: 1, 2, 3, 4, 5, 6, 7, 8, 9
- immune response and tyrosine kinase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
- immune response and tyrosine kinase receptor: 1, 2, 3, 4, 5, 6, 7
- immune response and vivo treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- immune response and widely study: 1, 2, 3, 4
- immune response enhance and mucosal adjuvant: 1, 2
- immune response enhance and plasmid dna: 1
- immune response enhance and protein antigen: 1, 2
- mucosal adjuvant and plasmid dna: 1, 2
- mucosal adjuvant and protein antigen: 1, 2, 3
- mucosal route and plasmid dna: 1
- mucosal route and protein antigen: 1, 2
- plasmid dna and protein antigen: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- plasmid dna and target ability: 1
- plasmid dna and tyrosine kinase: 1, 2
Co phrase search for related documents, hyperlinks ordered by date